DumontL, MardirosoffC, and TramerMR. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: Quantitative systematic review. BMJ, 321:267–272.
2.
GertschJH, LipmanGS, HolckPS, MerrittA, MulcahyA, FisherRS, BasnyatB, AllisonE, HanzelkaA, HanzanA, MeyersZ, OdegaardJ, PookB, ThompsonM, SlomovicB, WahlbergH, WilshawV, WeissEA, and ZafrenK. (2010). Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: The headache evaluation at altitude trial (HEAT). Wilderness Environ Med, 21:236–243.
3.
HackettPH, RennieD, and LevineHD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet, 2:1149–1155.
4.
KayserB, DumontL, LysakowskiC, CombescureC, HallerG, and TramerMR. (2012). Reappraisal of acetazolamide for the prevention of acute mountain sickness: A systematic review and meta-analysis. High Alt Med Biol, 13:82–92.
5.
LipmanGS, JurkiewiczC, BurnierA, MarvelJ, PhillipsC, LowryC, HawkinsJ, NavlytA, and SwensonER. (2020). A randomized controlled trial of the lowest effective dose of acetazolamide for acute mountain sickness prevention. Am J Med, 133:e706–e715.
6.
LipmanGS, JurkiewiczC, Winstead-DerlegaC, NavlytA, BurnsP, WalkerA, PhillipsC, ReillyA, BurnierA, RomeroJ, WarnerK, and HackettP. (2019). Day of ascent dosing of acetazolamide for prevention of acute mountain sickness. High Alt Med Biol, 20:271–278.
7.
LowEV, AveryAJ, GuptaV, SchedlbauerA, and GrocottMP. (2012). Identifying the lowest effective dose of acetazolamide for the prophylaxis of acute mountain sickness: Systematic review and meta-analysis. BMJ, 345:e6779.
8.
RitchieND, BaggottAV, and ToddWTA. (2012). Acetazolamide for the prevention of acute mountain sickness—A systematic review and meta-analysis. J Travel Med, 19:298–307.
9.
ToussaintCM, KenefickRW, PetrassiFA, MuzaSR, and CharkoudianN. (2021). Altitude, acute mountain sickness, and acetazolamide: Recommendations for rapid ascent. High Alt Med Biol, 22:5–13.
